Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Treatment With Liatermin in Parkinson's Disease
NCT00111982Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2003
- Primary completion
- Nov 2005
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of glial cell line-derived neurotrophic factor in Parkinson's disease (PD), sponsored by Amgen. Started Dec 2003; status: completed.
02
Drugs
glial cell line-derived neurotrophic factor
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00111982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111982.